St. Renatus, LLC is pleased to announce that its first product, Kovanaze™ (tetracaine HCl and oxymetazoline HCl) Nasal Spray, is now approved by the United States Food & Drug Administration (FDA).

Kovanaze— a new dental anesthetic nasal spray in development for over ten years—received FDA approval on June 29, 2016. We are excited to bring Kovanaze to dentists and patients, and will post a specific website about the new anesthetic product in the near future.


is now approved by the FDAKovanaze™ Package Insert

About St. Renatus

St. Renatus is working to be a catalyst for enhanced patient comfort and care.

Learn More

Leadership Team

Our dedicated and energetic team is committed to positively impacting dentistry.

Learn More

St. Renatus Cares

St. Renatus team members advocate for oral health care in children and adults.

Learn More

St. Renatus LLC, a privately held company based in Fort Collins, Colorado, is pleased… Read More »


FDA gives approval stamp to Kovanaze™.

Click here to view Kovanaze™ on the FDA website.

Are you looking for a career?St. Renatus is currently hiring

St. Renatus offers a dynamic environment that values all people. If you are looking for a dedicated and energetic team committed to positively impacting dentistry, then St. Renatus may be right for you.

Copyright © 2016 St. Renatus. All Rights Reserved.

Subscribe for Kovanaze Information

Subscribe for Kovanaze Information

Join our mailing list to receive the latest news and updates regarding Kovanaze.

You have Successfully Subscribed!